Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Genzyme Shares Rise as Sanofi Buyout Reports Increase

By Pharmaceutical Processing | July 29, 2010

INDIANAPOLIS (AP) — A Jefferies & Co. analyst raised her price target Thursday for shares of Genzyme Corp., citing media reports that French drugmaker Sanofi-Aventis SA will make an offer to buy the biotechnology drugmaker.

Analyst Eun K. Yang set a new price target at $80, picking the midpoint between the $75-per-share price at which the analyst believes Genzyme would be interested in starting acquisition talks and the $85 sale price it may want. The previous price target was $63.

“In anticipation of the formal offer and price negotiation, we expect (Genzyme) shares will likely continue to trade up,” Yang wrote.

Genzyme shares started climbing earlier this month from about $50 after reports surfaced that Sanofi was interested in an acquisition.

Genzyme, which is based in Cambridge, Mass., has been struggling for months with manufacturing problems that reduced production of two key drugs for genetic diseases, Cerezyme and Fabrazyme. It said last week its profit shrank drastically in the second quarter because of falling sales and charges partly connected to those problems.

Yang said in her note the $85-per-share price reflects the company’s “turnaround value.”

The New York Times reported late Wednesday Sanofi likely will make an offer of up to $70 per share, or more than $18 billion total, for Genzyme, citing anonymous sources.

Sanofi CEO Christopher Viehbacher declined to comment Thursday on the takeover bid reports. He said the company was under no pressure to do any deals.

Sanofi, which is based in Paris, said Thursday its net income rose 61 percent to 1.7 billion euros ($2.2 billion) in the second quarter.

In premarket trading, Genzyme shares changed hands at $71.97, up nearly 6 percent from Wednesday’s close.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE